Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
EGP-437 1.6 mA-min at 0.4 with EyeGate II System · 1 trial · 1 indication
Proportion of subjects with an anterior chamber cell (ACC) score of zero at Days 14 and 28
| Arm | Type | Description |
|---|---|---|
| EGP-437 1.6 mA-min at 0.4 mA | ACTIVE_COMPARATOR | Ocular iontophoresis with EGP 437 1.6 mA-min at 0.4 mA |
| EGP-437 4.8 mA-min at 1.2 mA | ACTIVE_COMPARATOR | Ocular iontophoresis with EGP-437 4.8 mA-min at 1.2 mA |
| EGP-437 10.0 mA-min at 2.5 mA | ACTIVE_COMPARATOR | Ocular iontophoresis with EGP-437 10.0 mA-min at 2.5 mA |
| EGP-437 14.0 mA-min at 3.5 mA | ACTIVE_COMPARATOR | Ocular iontophoresis with EGP-437 14.0 mA-min at 3.5 mA |
| Name | Type | Description |
|---|---|---|
| EGP-437 1.6 mA-min at 0.4 with EyeGate® II System | DRUG | Ocular Iontophoresis with EGP-437 1.6 mA-min at 0.4 mA delivered via EyeGate® II Drug Delivery System |
| EGP-437 4.8 mA-min at 1.2 mA with EyeGate® II System | DRUG | Ocular Iontophoresis with EGP-437 4.8 mA-min at 1.2 mA delivered via EyeGate® II Drug Delivery System |
| EGP-437 10.0 mA-min at 2.5 mA with EyeGate® II System | DRUG | Ocular Iontophoresis with EGP-437 10.0 mA-min at 2.5 mA delivered via EyeGate® II Drug Delivery System |
| EGP-437 14.0 mA-min at 3.5 mA with EyeGate® II System | DRUG | Ocular Iontophoresis with EGP-437 14.0 mA-min at 3.5 mA delivered via EyeGate® II Drug Delivery System |
Inclusion Criteria: • Non-infectious anterior uveitis Exclusion Criteria: * Uveitis of infectious etiology * Previous anterior uveitis episode ≤ 4 weeks prior to baseline * Intraocular pressure (IOP) ≥ 25 mmHg at baseline, a history of glaucoma, and/or patients who require ocular anti-hypertensiv...
EGP-437 1.6 mA-min at 0.4 with EyeGate II System is an investigational small molecule being developed for the treatment of anterior uveitis, an inflammatory condition of the eye. It is administered via iontophoresis using the EyeGate II System to deliver dexamethasone phosphate. The drug is currently in Phase 2 clinical development.
EGP-437 1.6 mA-min at 0.4 with EyeGate II System delivers dexamethasone phosphate, a corticosteroid, through the eye using iontophoresis. This method uses a mild electrical current to enhance drug penetration into ocular tissues, potentially reducing inflammation associated with anterior uveitis. The specific molecular target is not disclosed in available information.
EGP-437 1.6 mA-min at 0.4 with EyeGate II System is being developed by Kiora Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol KPRX. The company is focused on ophthalmic therapies and is advancing this candidate through clinical trials for anterior uveitis.
EGP-437 1.6 mA-min at 0.4 with EyeGate II System is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 2 trial has been completed, and the drug is not currently in active clinical trials.
EGP-437 1.6 mA-min at 0.4 with EyeGate II System has been studied in one completed Phase 2 trial, identified as NCT00694135. This randomized, double-blind, active-controlled study evaluated the safety and efficacy of iontophoresis and dexamethasone phosphate for treating anterior uveitis, enrolling 40 participants in the United States and India.
EGP-437 1.6 mA-min at 0.4 with EyeGate II System is a specific formulation and delivery method for dexamethasone phosphate. The drug combines the corticosteroid dexamethasone phosphate with the EyeGate II System, which uses iontophoresis to administer the medication. It is not simply dexamethasone phosphate alone but a proprietary delivery approach.